{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:44:40Z","timestamp":1787071480098,"version":"build-2736575974"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Essential thrombocythemia (ET) and polycythemia vera (PV) are rare chronic myeloproliferative neoplasms that have hemostatic complications (i.e., thrombosis and hemorrhage), leading to morbidity and mortality. Treatment in ET or PV is directed toward preventing thrombotic consequences. However, the increased risk of bleeding may complicate antithrombotic therapy in these patients. Thrombosis may occur in both arterial and venous vascular beds. Arterial thrombosis, such as acute coronary syndrome (ACS), is more frequent than venous thrombosis. Both ET and PV can initially present as an ACS, the management of which is highly challenging in the absence of clinical guidelines that are dedicated to such patients. The management of ACS in patients with ET or PV has not been well described in literature. Herein, this review discusses the pathogenesis, characteristics, and management of ACS in patients with ET or PV.<\/jats:p>","DOI":"10.4103\/heartviews.heartviews_81_25","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:00:30Z","timestamp":1763730030000},"page":"175-187","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Acute Coronary Syndrome in Essential Thrombocythemia and Polycythemia Vera"],"prefix":"10.4103","volume":"26","author":[{"given":"Rasha","family":"Kaddoura","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Alexandria New Medical Center, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Rudwan","sequence":"additional","affiliation":[{"name":"Academic Health System, Medical Research Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elyas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"R1-20260420","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ajh.23881","article-title":"Coronary microvascular dysfunction due to essential thrombocythemia and policythemia Vera: The missing piece in the puzzle of their increased cardiovascular risk?","volume":"90","author":"Vianello","year":"2015","journal-title":"Am J Hematol"},{"key":"R2-20260420","first-page":"397","article-title":"Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia Vera","volume":"16","author":"P\u00f3sfai","year":"2016","journal-title":"Anatol J Cardiol"},{"key":"R3-20260420","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1538-7836.2009.03469.x","article-title":"Long-term outcome after percutaneous coronary intervention in patients with essential thrombocythemia","volume":"7","author":"Campo","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R4-20260420","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2796.1998.00314.x","article-title":"Acute coronary disease in essential thrombocythemia and polycythemia Vera","volume":"244","author":"Rossi","year":"1998","journal-title":"J Intern Med"},{"key":"R5-20260420","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"key":"R6-20260420","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia Vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"R7-20260420","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia Vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am J Hematol"},{"key":"R8-20260420","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2022.04.002","article-title":"Cardiovascular disease in myeloproliferative neoplasms: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Leiva","year":"2022","journal-title":"JACC CardioOncol"},{"key":"R9-20260420","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia Vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"R10-20260420","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia Vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"R11-20260420","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","article-title":"In contemporary patients with polycythemia Vera, rates of thrombosis and risk factors delineate a new clinical epidemiology","volume":"124","author":"Barbui","year":"2014","journal-title":"Blood"},{"key":"R12-20260420","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.repc.2018.09.014","article-title":"A rare cause of acute coronary syndromes in young adults \u2013 Myeloproliferative neoplasms: A case series","volume":"38","author":"Cengiz","year":"2019","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"R13-20260420","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15647","article-title":"A guideline for the management of specific situations in polycythaemia Vera and secondary erythrocytosis: A British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"key":"R14-20260420","doi-asserted-by":"crossref","first-page":"100081","DOI":"10.1016\/j.tru.2021.100081","article-title":"Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological","volume":"5","author":"Kelliher","year":"2021","journal-title":"Thrombosis Update"},{"key":"R15-20260420","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.repc.2019.10.005","article-title":"When specialties intersect: Acute coronary syndrome as the first clinical manifestation of myeloproliferative neoplasms","volume":"38","author":"Toste","year":"2019","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"R16-20260420","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1055\/a-1742-0361","article-title":"Rare causes of acute coronary syndrome: The JAK2 V617F mutation-positive myeloproliferative neoplasms: A cardio-hematological perspective","volume":"122","author":"Cantoni","year":"2022","journal-title":"Thromb Haemost"},{"key":"R18-20260420","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/09537100600758677","article-title":"Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia Vera: A distinct aspirin-responsive and coumadin-resistant arterial thrombophilia","volume":"17","author":"Michiels","year":"2006","journal-title":"Platelets"},{"key":"R19-20260420","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The haematocrit and platelet target in polycythemia Vera","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"key":"R20-20260420","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency>50% identifies patients with polycythemia Vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"key":"R21-20260420","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am J Hematol"},{"key":"R22-20260420","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia Vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"key":"R23-20260420","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"Suppl 2","key":"R24-20260420","doi-asserted-by":"crossref","first-page":"ehaa946.1630","DOI":"10.1093\/ehjci\/ehaa946.1630","article-title":"Acute coronary events in patients with myeloproliferative neoplasms- a nationwide analysis of patient characteristics and in-hospital outcomes","volume":"41","author":"Bhatia","year":"2020","journal-title":"Eur Heart J"},{"key":"R25-20260420","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/hematolrep15020040","article-title":"Risk factors for death or cardiovascular events after acute coronary syndrome in patients with myeloproliferative neoplasms","volume":"15","author":"Leiva","year":"2023","journal-title":"Hematol Rep"},{"key":"R26-20260420","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia Vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"key":"R27-20260420","doi-asserted-by":"crossref","first-page":"1369701","DOI":"10.3389\/fcvm.2024.1369701","article-title":"Prediction of acute coronary syndrome in patients with myeloproliferative neoplasms","volume":"11","author":"Huang","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"R28-20260420","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaccao.2023.03.014","article-title":"Outcomes of patients with myeloproliferative neoplasms admitted with myocardial infarction: Insights from national inpatient sample","volume":"5","author":"Leiva","year":"2023","journal-title":"JACC CardioOncol"},{"key":"R29-20260420","doi-asserted-by":"crossref","first-page":"119046","DOI":"10.1016\/j.atherosclerosis.2024.119046","article-title":"Readmission outcomes after acute coronary syndrome among patients with myeloproliferative neoplasms","volume":"401","author":"Leiva","year":"2025","journal-title":"Atherosclerosis"},{"key":"R30-20260420","doi-asserted-by":"crossref","first-page":"e027352","DOI":"10.1161\/JAHA.122.027352","article-title":"In-hospital outcomes of acute myocardial infarction with essential thrombocythemia and polycythemia Vera: Insights from the national inpatient sample","volume":"11","author":"Wu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R31-20260420","doi-asserted-by":"crossref","first-page":"286","DOI":"10.31083\/j.rcm2308286","article-title":"Bleeding complications in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"R32-20260420","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"R33-20260420","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"R34-20260420","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4172\/2329-8790.1000107","article-title":"Polycythemia Vera and acute coronary syndromes: Pathogenesis, risk factors and treatment","volume":"1","author":"Adel","year":"2013","journal-title":"J Hematol Thromb Dis"},{"key":"R35-20260420","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.amjcard.2004.08.015","article-title":"Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction","volume":"94","author":"Turakhia","year":"2004","journal-title":"Am J Cardiol"},{"key":"R36-20260420","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.amjcard.2019.04.049","article-title":"Effect of chronic hematologic malignancies on in-hospital outcomes of patients with ST-segment elevation myocardial infarction","volume":"124","author":"Patel","year":"2019","journal-title":"Am J Cardiol"},{"key":"R37-20260420","first-page":"1535","article-title":"Trends and outcomes following percutaneous coronary intervention in patients with myeloproliferative neoplasms: Insights from national database","volume":"105","author":"Ang","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"issue":"Suppl 1","key":"R38-20260420","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.ihj.2019.11.167","article-title":"Effect of polycythemia on percutaneous coronary intervention outcome","volume":"71","author":"Chetti","year":"2019","journal-title":"Indian Heart J"},{"issue":"Suppl 1","key":"R39-20260420","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1182\/blood-2019-124612","article-title":"Study on the possibility of emergency percutaneous coronary intervention (PCI) in myeloproliferative neoplasms (MPNs) patients with acute coronary syndrome (ACS)","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"R40-20260420","first-page":"S268","article-title":"Outcomes after coronary revascularization inpatients with polycythemia Vera and essential thrombocythemia","volume":"5","author":"Wahhab","year":"2012","journal-title":"Can J Cardiol"},{"key":"R41-20260420","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4070\/kcj.2011.41.7.417","article-title":"Very late stent thrombosis in a drug-eluting stent due to interruption of anti-platelet agents in patients with acute myocardial infarction and thrombocytosis","volume":"41","author":"Choi","year":"2011","journal-title":"Korean Circ J"},{"key":"R42-20260420","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2143\/AC.55.6.2005769","article-title":"Recurrent coronary stent thrombosis","volume":"55","author":"Goethals","year":"2000","journal-title":"Acta Cardiol"},{"issue":"Suppl 3","key":"R43-20260420","first-page":"S487","article-title":"Acute myocardial infarction as the initial manifestation of polycythemia Vera: An unusual presentation","volume":"25","author":"Thota","year":"2010","journal-title":"J Gen Intern Med"},{"issue":"Suppl 1","key":"R44-20260420","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/01.ccm.0000528560.40724.98","article-title":"A rare case of polycythemia Vera precipitating myocardial infarction","volume":"46","author":"Soni","year":"2018","journal-title":"Crit Care Med"},{"key":"R45-20260420","first-page":"520","article-title":"Very late coronary drug-eluting stent thrombosis in a patient with essential thrombocythemia: A case report of a rare association","volume":"13","author":"Mele","year":"2012","journal-title":"G Ital Cardiol (Rome)"},{"key":"R46-20260420","first-page":"428","article-title":"Acute coronary occlusion and in-stent thrombosis in a patient with essential thrombocythemia","volume":"45","author":"Turgut","year":"1998","journal-title":"Cathet Cardiovasc Diagn"},{"key":"R47-20260420","first-page":"163","article-title":"Is conventional antiplatelet therapy for the prevention of coronary stent thrombosis always safe? A case report of a patient with polycythemia Vera","volume":"5","author":"Zavalloni","year":"2004","journal-title":"Ital Heart J"},{"key":"R48-20260420","first-page":"3512","article-title":"Acute myocardial infarction and sub-acute stent thrombosis associated with occult essential thrombocythemia","volume":"127","author":"Isilak","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"R49-20260420","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s00380-016-0798-x","article-title":"JAK2 mutation and acute coronary syndrome complicated with stent thrombosis","volume":"31","author":"Inami","year":"2016","journal-title":"Heart Vessels"},{"key":"R50-20260420","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2169\/internalmedicine.2083-18","article-title":"In-stent massive thrombi formation during primary percutaneous coronary intervention in a patient with acute myocardial infarction complicated with essential thrombocythemia","volume":"58","author":"Shoji","year":"2019","journal-title":"Intern Med"},{"key":"R51-20260420","first-page":"4104","article-title":"Subacute intracoronary stent thrombosis in a patient with polycythaemia Vera","volume":"168","author":"Hvelplund","year":"2006","journal-title":"Ugeskr Laeger"},{"key":"R52-20260420","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3892\/etm.2013.1389","article-title":"Surgical treatment of a ventricular aneurysm in a patient with essential thrombocythemia complicated by acute myocardial infarction: A case report","volume":"7","author":"Wang","year":"2014","journal-title":"Exp Ther Med"},{"key":"R53-20260420","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/107602969900500408","article-title":"Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia","volume":"5","author":"Michiels","year":"1999","journal-title":"Clin Appl Thromb Hemost"},{"key":"R54-20260420","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia Vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"R55-20260420","first-page":"s138","article-title":"Is dual antiplatelet therapy safe in patients with myeloproliferative disorders? Report from a single-center cohort","volume":"10","author":"Nichele","year":"2012","journal-title":"Blood Trans"},{"key":"R56-20260420","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1538-7836.2010.04115.x","article-title":"Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease","volume":"9","author":"Grove","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"R57-20260420","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2362.1994.tb02419.x","article-title":"The megakaryocyte platelet system and vascular disease","volume":"24","author":"Brown","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"R58-20260420","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1073\/pnas.112202999","article-title":"Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets","volume":"99","author":"Rocca","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R59-20260420","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1055\/s-0041-1731309","article-title":"Lower antiplatelet effect of aspirin in essential thrombocythemia than in coronary artery disease","volume":"5","author":"Pedersen","year":"2021","journal-title":"TH Open"},{"key":"R60-20260420","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"key":"R61-20260420","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"Rocca","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"R62-20260420","first-page":"893","article-title":"Platelet function and coagulation abnormalities in polycythemia Vera patients: Effects of low-dose aspirin","volume":"4","author":"Cacciola","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"R63-20260420","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1160\/TH08-03-0186","article-title":"Immature platelets in patients with acute coronary syndromes","volume":"101","author":"Grove","year":"2009","journal-title":"Thromb Haemost"},{"key":"R64-20260420","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/09537104.2012.738838","article-title":"Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction","volume":"24","author":"Funck-Jensen","year":"2013","journal-title":"Platelets"},{"key":"R65-20260420","doi-asserted-by":"crossref","first-page":"e016495","DOI":"10.1161\/JAHA.120.016495","article-title":"Pharmacodynamic comparison of ticagrelor monotherapy versus ticagrelor and aspirin in patients after percutaneous coronary intervention: The TEMPLATE (ticagrelor monotherapy and platelet reactivity) randomized controlled trial","volume":"9","author":"Johnson","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R66-20260420","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fimmu.2020.00705","article-title":"Platelet toll-like receptors mediate thromboinflammatory responses in patients with essential thrombocythemia","volume":"11","author":"Mar\u00edn Oyarz\u00fan","year":"2020","journal-title":"Front Immunol"},{"key":"R67-20260420","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.3390\/ijms21176150","article-title":"Revisiting platelets and toll-like receptors (TLRs): At the interface of vascular immunity and thrombosis","volume":"21","author":"Hally","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R68-20260420","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/09537104.2018.1479520","article-title":"The effects of aspirin and ticagrelor on Toll-like receptor (TLR)-mediated platelet activation: Results of a randomized, cross-over trial","volume":"30","author":"Hally","year":"2019","journal-title":"Platelets"},{"key":"R69-20260420","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10557-019-06932-7","article-title":"Ticagrelor inhibits toll-like and protease-activated receptor mediated platelet activation in acute coronary syndromes","volume":"34","author":"Wadowski","year":"2020","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Heart Views"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/heartviews.heartviews_81_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:46:43Z","timestamp":1787068003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/heartviews.heartviews_81_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/heartviews.heartviews_81_25","relation":{},"ISSN":["1995-705X","0976-5123"],"issn-type":[{"value":"1995-705X","type":"print"},{"value":"0976-5123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-06-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}